The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.m

ILD with a granulomatous component

Publications

Tissot C, Carsin A, Freymond N, Pacheco Y, Devouassoux G

Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy.

The European respiratory journal. 2013;41(1):246-7

Berthod G, Lazor R, Letovanec I, Romano E, Noirez L, Mazza Stalder J, Speiser DE, Peters S, Michielin O

Pulmonary sarcoid-like granulomatosis induced by ipilimumab.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(17):e156-9

Wilgenhof S, Morlion V, Seghers AC, Du Four S, Vanderlinden E, Hanon S, Vandenbroucke F, Everaert H, Neyns B

Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor.

Anticancer research. 2012;32(4):1355-9

Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L

Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient.

Dermatology (Basel, Switzerland). 2009;218(1):69-70